Lenalidomide Olainfarm

Lenalidomide, the active ingredient in Lenalidomide Olainfarm, is an Immunomodulatory drug (IMiD) presented as a tablet for oral use. It is indicated for certain blood cancers and is administered under medical supervision.

GNH USA supplies Lenalidomide Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow. - Multiple myeloma: improves progression‑free survival and overall response rates. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. - Mantle cell lymphoma: contributes to disease control when combined with other agents.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: mild to moderate loose stools. - Rash: skin erythema or pruritus. - Nausea: occasional upset stomach. - Constipation: reduced bowel movements. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Patients should be monitored for known risks and contraindications before and during therapy. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis prophylaxis: assess need for anticoagulation in high‑risk patients. - Renal function: adjust monitoring if creatinine clearance is reduced. - Hepatic impairment: evaluate liver function tests regularly. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely): - CYP450 substrates metabolized by CYP2C19: possible altered plasma levels. - NSAIDs: may exacerbate renal toxicity. - Vaccines: live vaccines should be avoided during treatment.